RESUMO
BALB/c mice were immunized with 1 X 10(7) heat-killed Mycobacterium lepraemurium (Mlm) via the hind foot pad. Four weeks later, the animals were infected with 1 X 10(9) Mlm intraperitoneally. Skin test studies, using footpad swelling as a parameter, indicated the development of skin reactivity to Mlm and M. leprae cell extracts. Immunized animals that were infected showed positive reactions to both antigens by the second week. This persisted up to fourteen weeks, at which time, bacillary restriction was also observed in the spleens and livers. Non-immunized infected animals, on the other hand showed a decline in skin reactivity to the two antigens used, and also showed proliferation of Mlm in the two organs examined. Animals receiving heat-killed Mlm or sensitized splenocytes when challenged with 5 X 10(3) M. leprae via hind foot pad, did not show inhibition of the infecting agent, thus indicating a lack of cross-protection.
Assuntos
Imunização , Infecções por Mycobacterium/imunologia , Mycobacterium lepraemurium/imunologia , Animais , Feminino , Temperatura Alta , Imunização Passiva , Fígado/microbiologia , Transfusão de Linfócitos , Linfócitos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Infecções por Mycobacterium/microbiologia , Mycobacterium lepraemurium/isolamento & purificação , Testes Cutâneos , Baço/imunologia , Baço/microbiologiaAssuntos
Complexo Antígeno-Anticorpo/análise , Hanseníase/imunologia , Anticorpos Antibacterianos/análise , Transfusão de Sangue , DNA Bacteriano/imunologia , Quimioterapia Combinada , Humanos , Antígeno de Mitsuda/imunologia , Hanseníase/tratamento farmacológico , Transfusão de Linfócitos , Mycobacterium leprae/imunologia , RecidivaAssuntos
Hanseníase/terapia , Animais , Vacinas Bacterianas/uso terapêutico , Transfusão de Sangue , Humanos , Hanseníase/imunologia , Levamisol/uso terapêutico , Transfusão de Linfócitos , Camundongos , Mycobacterium leprae/imunologia , Troca Plasmática , Timo/transplante , Fator de Transferência/uso terapêuticoRESUMO
An attempt was made to repair cell-mediated immunity in 7 patients suffering from lepromatous leprosy and severe erythema nodosum leprosum by intravenous infusion of 400 million allogeneic blood lymphocytes on 3 occasions. The lymphocytes were obtained from lepromin and tuberculin-positive subjects and were inactivated in vitro by treatment with mitomycin C. Immunotherapy with inactivated lymphocytes only modified the severity of erythema nodosum leprosum, without altering other aspects of the disease.